Next Article in Journal
Intention to Be Vaccinated for COVID-19 among Italian Nurses during the Pandemic
Next Article in Special Issue
Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis
Previous Article in Journal
Post-COVID Syndrome: An Insight on Its Pathogenesis
Previous Article in Special Issue
Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 9
Issue 5
10.3390/vaccines9050498
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2

by
Chotiwat Seephetdee
1,
Nattawut Buasri
1,
Kanit Bhukhai
2,
Kitima Srisanga
1,
Suwimon Manopwisedjaroen
3,
Sarat Lertjintanakit
1,
Nut Phueakphud
1,
Chatbenja Pakiranay
1,
Niwat Kangwanrangsan
4,
Sirawat Srichatrapimuk
5,
Suppachok Kirdlarp
5,
Somnuek Sungkanuparph
5,
Somchai Chutipongtanate
5,6,7,
Arunee Thitithanyanont
3,
Suradej Hongeng
6 and
Patompon Wongtrakoongate
1,8,*
1
Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
2
Department of Physiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
3
Department of Microbiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
4
Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
5
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, Thailand
6
Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
7
Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
8
Center for Neuroscience, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
*
Author to whom correspondence should be addressed.
Vaccines 2021, 9(5), 498; https://doi.org/10.3390/vaccines9050498
Submission received: 2 March 2021 / Revised: 4 April 2021 / Accepted: 5 May 2021 / Published: 12 May 2021
(This article belongs to the Special Issue The COVID Vaccine)
Browse Figures
Review Reports Versions Notes

Abstract

Updated and revised versions of COVID-19 vaccines are vital due to genetic variations of the SARS-CoV-2 spike antigen. Furthermore, vaccines that are safe, cost-effective, and logistic-friendly are critically needed for global equity, especially for middle- to low-income countries. Recombinant protein-based subunit vaccines against SARS-CoV-2 have been reported using the receptor-binding domain (RBD) and the prefusion spike trimers (S-2P). Recently, a new version of prefusion spike trimers, named HexaPro, has been shown to possess two RBD in the “up” conformation, due to its physical property, as opposed to just one exposed RBD found in S-2P. Importantly, this HexaPro spike antigen is more stable than S-2P, raising its feasibility for global logistics and supply chain. Here, we report that the spike protein HexaPro offers a promising candidate for the SARS-CoV-2 vaccine. Mice immunized by the recombinant HexaPro adjuvanted with aluminum hydroxide using a prime-boost regimen produced high-titer neutralizing antibodies for up to 56 days after initial immunization against live SARS-CoV-2 infection. Also, the level of neutralization activity is comparable to that of convalescence sera. Our results indicate that the HexaPro subunit vaccine confers neutralization activity in sera collected from mice receiving the prime-boost regimen.
Keywords: HexaPro; spike; SARS-CoV-2; vaccine HexaPro; spike; SARS-CoV-2; vaccine

Share and Cite

MDPI and ACS Style

Seephetdee, C.; Buasri, N.; Bhukhai, K.; Srisanga, K.; Manopwisedjaroen, S.; Lertjintanakit, S.; Phueakphud, N.; Pakiranay, C.; Kangwanrangsan, N.; Srichatrapimuk, S.; et al. Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2. Vaccines 2021, 9, 498. https://doi.org/10.3390/vaccines9050498

AMA Style

Seephetdee C, Buasri N, Bhukhai K, Srisanga K, Manopwisedjaroen S, Lertjintanakit S, Phueakphud N, Pakiranay C, Kangwanrangsan N, Srichatrapimuk S, et al. Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2. Vaccines. 2021; 9(5):498. https://doi.org/10.3390/vaccines9050498

Chicago/Turabian Style

Seephetdee, Chotiwat, Nattawut Buasri, Kanit Bhukhai, Kitima Srisanga, Suwimon Manopwisedjaroen, Sarat Lertjintanakit, Nut Phueakphud, Chatbenja Pakiranay, Niwat Kangwanrangsan, Sirawat Srichatrapimuk, and et al. 2021. "Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2" Vaccines 9, no. 5: 498. https://doi.org/10.3390/vaccines9050498

APA Style

Seephetdee, C., Buasri, N., Bhukhai, K., Srisanga, K., Manopwisedjaroen, S., Lertjintanakit, S., Phueakphud, N., Pakiranay, C., Kangwanrangsan, N., Srichatrapimuk, S., Kirdlarp, S., Sungkanuparph, S., Chutipongtanate, S., Thitithanyanont, A., Hongeng, S., & Wongtrakoongate, P. (2021). Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2. Vaccines, 9(5), 498. https://doi.org/10.3390/vaccines9050498

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop